BEUDAMED
    FDA Adverse Event Injury Summary report: N

    EVOLUT FX VALVE

    MDR report key: 22173077 · Received June 9, 2025

    Report

    Report Number
    2025587-2025-04141
    Event Type
    Injury
    Date Received
    June 9, 2025
    Date of Event
    December 23, 2024
    Report Date
    June 9, 2025
    Manufacturer
    MEDTRONIC HEART VALVES DIVISION
    Product Code
    NPT
    PMA / PMN Number
    P130021
    Adverse Event
    Yes
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    JA
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    CITATION: HARIMOCHI ET AL. COMPARISON OF REMIMAZOLAM AND SEVFLURANE FOR GENERAL ANESTHESIA DURING TRANSCATHETER AORTIC VALVE IMPLANTATION: A RANDOMIZED TRIAL. CAN J ANESTH. MAR;72(3):397-408. 2025. 10.1007/S12630-024-02900-4. EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

    Description of Event or Problem · 0

    LITERATURE WAS REVIEWED REGARDING THE COMPARISON OF REMIMAZOLAM AND SEVOFLURANE FOR GENERAL ANESTHESIA DURING TRANSCATHETER AORTIC VALVE IMPLANTATION.  THE STUDY POPULATION INCLUDED 60 PATIENTS FROM A SINGLE CENTER.  MULTIPLE MANUFACTURER¿S DEVICES WERE IMPLANTED IN THE STUDY POPULATION; ONE PATIENT WAS IMPLANTED WITH A MEDTRONIC EVOLUT FX BIOPROSTHETIC VALVE.  AMONG ALL PATIENTS, CLINICAL OBSERVATIONS INCLUDED: STROKE, BLEEDING COMPLICATION, ARRHYTHMIA REQUIRING PERMANENT PACEMAKER IMPLANT, UNSPECIFIED STRUCTURAL VALVE DYSFUNCTION, AND VALVE THROMBOSIS.  NO FURTHER INFORMATION WAS PROVIDED PERTAINING TO MEDTRONIC PRODUCTS.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1477468 EVOLUT FX VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV NPT MEDTRONIC HEART VALVES DIVISION EVOLUTFX-23

    Patients

    Seq Age Sex Outcome Treatment
    1 NA Unknown Required Intervention| H| L